Trial Outcomes & Findings for Airway Responses During Desflurane Anesthesia Via a Laryngeal Mask Airway: Effects of Fentanyl Pretreatment (NCT NCT01277861)

NCT ID: NCT01277861

Last Updated: 2013-03-15

Results Overview

The data provided below include participants who moved (includes all grades of movement ie, mild, moderate and severe).

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

100 participants

Primary outcome timeframe

Induction of Anesthesia

Results posted on

2013-03-15

Participant Flow

Patients were recruited for the study in the preoperative period.

Participants were included based on inclusion/exclusion criteria. Participants were excluded if muscle relaxation was necessary for the surgery.

Participant milestones

Participant milestones
Measure
FENTANYL
FENTANYL
SALINE
SALINE
Overall Study
STARTED
51
49
Overall Study
COMPLETED
49
47
Overall Study
NOT COMPLETED
2
2

Reasons for withdrawal

Reasons for withdrawal
Measure
FENTANYL
FENTANYL
SALINE
SALINE
Overall Study
Physician Decision
2
2

Baseline Characteristics

Airway Responses During Desflurane Anesthesia Via a Laryngeal Mask Airway: Effects of Fentanyl Pretreatment

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
FENTANYL
n=49 Participants
FENTANYL
SALINE
n=47 Participants
SALINE
Total
n=96 Participants
Total of all reporting groups
Age, Categorical
<=18 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Age, Categorical
Between 18 and 65 years
49 Participants
n=5 Participants
47 Participants
n=7 Participants
96 Participants
n=5 Participants
Age, Categorical
>=65 years
0 Participants
n=5 Participants
0 Participants
n=7 Participants
0 Participants
n=5 Participants
Sex: Female, Male
Female
25 Participants
n=5 Participants
25 Participants
n=7 Participants
50 Participants
n=5 Participants
Sex: Female, Male
Male
24 Participants
n=5 Participants
22 Participants
n=7 Participants
46 Participants
n=5 Participants
Body Mass Index
26.8 kg/m2
STANDARD_DEVIATION 4.3 • n=5 Participants
26.8 kg/m2
STANDARD_DEVIATION 4.7 • n=7 Participants
26.8 kg/m2
STANDARD_DEVIATION 4.5 • n=5 Participants

PRIMARY outcome

Timeframe: Induction of Anesthesia

Population: Per protocol

The data provided below include participants who moved (includes all grades of movement ie, mild, moderate and severe).

Outcome measures

Outcome measures
Measure
Fentanyl Pretreatment Group
n=49 Participants
Fentanyl 1 µg/kg (constituted to 10 ml with saline) prior to induction of anesthesia.
Saline Pretreatment Group
n=47 Participants
Saline 10 ml prior to induction of anesthesia.
Movement
8 Participants, number
24 Participants, number

SECONDARY outcome

Timeframe: Induction of Anesthesia

Population: Per protocol

Apnea defined as no breathing for at least 30 s.

Outcome measures

Outcome measures
Measure
Fentanyl Pretreatment Group
n=49 Participants
Fentanyl 1 µg/kg (constituted to 10 ml with saline) prior to induction of anesthesia.
Saline Pretreatment Group
n=47 Participants
Saline 10 ml prior to induction of anesthesia.
Apnea
46 Participants, number
30 Participants, number

SECONDARY outcome

Timeframe: Intraoperative period

Population: Per protocol

Data include patients who coughed irrespective of the degree of coughing.

Outcome measures

Outcome measures
Measure
Fentanyl Pretreatment Group
n=49 Participants
Fentanyl 1 µg/kg (constituted to 10 ml with saline) prior to induction of anesthesia.
Saline Pretreatment Group
n=47 Participants
Saline 10 ml prior to induction of anesthesia.
Coughing
1 Participants, number
6 Participants, number

Adverse Events

FENTANYL

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

SALINE

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Girish P. Joshi, MD

University of Texas Southwestern Medical Center at Dallas

Phone: 214-590-7259

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place